<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pitsios, C.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, D.</style></author><author><style face="normal" font="default" size="100%">Kompoti, E.</style></author><author><style face="normal" font="default" size="100%">Manoussakis, E.</style></author><author><style face="normal" font="default" size="100%">Garris, V.</style></author><author><style face="normal" font="default" size="100%">Petalas, K.</style></author><author><style face="normal" font="default" size="100%">Tassios, I.</style></author><author><style face="normal" font="default" size="100%">Baibas, N.</style></author><author><style face="normal" font="default" size="100%">Kontou-Fili, K.</style></author><author><style face="normal" font="default" size="100%">Saxoni-Papageorgiou, P.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Allergy Asthma Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Allergic</style></keyword><keyword><style  face="normal" font="default" size="100%">Intranasal Adolescent Adult Anti-Allergic Agents Child Drug Administration Schedule Female Humans Male Middle Aged Nedocromil Pregnadienediols Rhinitis</style></keyword><keyword><style  face="normal" font="default" size="100%">Seasonal</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/16729779</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">96</style></volume><pages><style face="normal" font="default" size="100%">673-8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The preventive use of medications has been proposed to be effective in the treatment of seasonal rhinitis.|To evaluate the efficacy and safety of mometasone furoate and nedocromil sodium nasal sprays as prophylactic treatment for moderate to severe seasonal allergic rhinitis (SAR).|Sixty-one patients were recruited from 3 referral allergy centers. Inclusion criteria were history of SAR for 2 years or longer, sensitization to relevant local pollen (grasses, Parietaria, and olive), and age older than 12 years.|An open-label, randomized, parallel-group, &quot;real-life&quot; study design was used. Patients received mometasone furoate nasal spray once daily or nedocromil sodium nasal spray 3 times daily starting 2 to 4 weeks before the pollen season and continuing for up to 4 months. Instructions regarding the use of additional medications were given. Diary cards recording symptoms, use of medication, and adverse events were kept by the patients.|All 61 patients completed the study. The prophylactic use of mometasone furoate vs nedocromil sodium led to significantly more days without symptoms (75.1% vs 54.5%; P &lt; .001). The mometasone furoate group also had lower nasal symptom scores (mean, 1.4 vs 2.9; median, 0 vs 2; P &lt; .001) and was more satisfied (93.1% vs 43.5%; P &lt; .001). No serious adverse event was recorded, and there was no difference between the treatments in any adverse event.|Prophylactic administration of mometasone furoate before the pollen season is safe and may lead to improved control of SAR compared with the use of nedocromil sodium.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>